Table 1.
Adjuvant Colon Cancer Trials Included
| Trial | Accrual Period | No. of Patients | Patients Age ≥ 70 Years (%) | Experimental Treatment Arm* | Stage III (%)† |
|---|---|---|---|---|---|
| Oxaliplatin | |||||
| MOSAIC | 1998 to 2001 | 2,246 | 14 | FOLFOX4 | 60 |
| NSABP-C07 | 2000 to 2002 | 2,434 | 16 | FLOX | 71 |
| XELOXA | 2003 to 2004 | 1,862 | 22 | XELOX | 100 |
| Irinotecan | |||||
| CALGB-89803 | 1999 to 2001 | 1,263 | 24 | IFL | 98 |
| PETACC-3 | 2000 to 2002 | 3,186 | 13 | FOLFIRI | 71 |
| Oral fluoropyrimidine | |||||
| NSABP-C06 | 1997 to 1999 | 1,557 | 23 | Uracil/tegafur | 53 |
| X-ACT | 1998 to 2001 | 1,983 | 20 | Capecitabine | 100 |
Abbreviations: CALGB, Cancer and Leukemia Group B; FLOX, bolus intravenous fluorouracil, leucovorin, and oxaliplatin; FOLFIRI, infusional fluorouracil, leucovorin, and irinotecan; FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; IFL, bolus intravenous fluorouracil, leucovorin, and irinotecan; MOSAIC, Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer; NSABP, National Adjuvant Breast and Bowel Project; PETACC, Pan-European Trials in Adjuvant Colon Cancer; X-ACT, Xeloda in Adjuvant Colon Cancer Therapy; XELOX, Xeloda and oxaliplatin; XELOXA, Xeloda and Oxaliplatin in Adjuvant Colon Cancer Treatment.
Compared with control arm of intravenous flourouracil and leucovorin.
Remaining patients had stage II disease or unknown stage.